Vortioxetine Market Report 2024 (Global Edition)

Global Vortioxetine Market Report 2024 Market Size Split by type (5 Mg Tablets, 10 Mg Tablet, 15 Mg Tablet, 20 Mg Tablet), by application (Depression, Generalized Anxiety Disorder, Attention Deficit H...

Vortioxetine Market Report Description

We have various report editions of Vortioxetine Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Vortioxetine Market Insights Video

Competitive Landscape of the Vortioxetine Market

The competitive landscape of the Vortioxetine market is characterized by a diverse range of players competing to gain market share through product innovation, strategic partnerships, and aggressive marketing efforts. These organizations use various development tactics such as mergers, acquisitions, partnerships, cooperation, and product launches to broaden their customer base on a global scale.

September 2019: Lundbeck has declared its intention to purchase Alder BioPharmaceuticals at a price of $18 per share, resulting in a valuation of about $2 billion for Alder.

Source:https://newsroom.lundbeckus.com/news-release/2019/lundbeck-to-acquire-alder-biopharmaceuticals-a-company-committed#:~:text=Under%20the%20terms%20of%20the,additional%20USD%202.00%20per%20share

 January 2020: Takeda has formed a research collaboration with the Massachusetts Institute of Technology (MIT) to accelerate advancements in artificial intelligence and healthcare. The MIT-Takeda Program is located in the MIT Jameel Clinic and is overseen by Professor James J. Collins. The program's steering committee is headed by Professor Anantha P. Chandrakasan, who serves as the dean of the MIT School of Engineering, and Anne Heatherington, the senior vice president and head of the Data Sciences Institute (DSI) at Takeda.

Source: https://news.mit.edu/2020/mit-school-engineering-takeda-join-to-advance-artificial-intelligence-health-research-0106

Top Companies Market Share in Vortioxetine Industry: (In no particular order of Rank)

• H.Lundbeck A/S
• Kanghong Pharmaceutical
• Takeda Pharmaceuticals USA
• Takeda Pharmaceutical
• Zydus Pharms
• CSPC Ouyi Pharmaceutical
• Brilliant Pharmaceutical
• Chiatai Tianqing
• Sino Biopharmaceutical
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Vortioxetine Market

Which Region Dominates the Vortioxetine Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024. It accounted for around 40% of the global revenue. North America dominates the Vortioxetine Hydrobromide Tablets market due to its strong electric car infrastructure. The market growth is driven by government incentives, increasing environmental consciousness, and investments in charging networks.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Vortioxetine market as a result of a significant increase in the use of electric vehicles, notably in China. The market is propelled by the advancement of infrastructure and technological innovation.

 

The current report Scope analyzes Vortioxetine Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Vortioxetine

According to Cognitive Market Research, the global Vortioxetine market size was estimated at USD 915.8 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 366.32 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2031. Healthcare experts in North America engage in close collaboration with pharmaceutical corporations. The utilization of vortioxetine is supported by guidelines and recommendations that are based on evidence from clinical studies. Ongoing medical education guarantees the use of well-informed prescription procedures.

• According to Cognitive Market Research, the US had a major share in the Vortioxetine market with a market size of USD 289.03 million in 2024 and is projected to grow at a CAGR of 8.6% during the forecast period. The demand is amplified by as public awareness efforts have emphasized the significance of mental health.
• The Canada Vortioxetine market had a market share of USD 43.96 million in 2024 and is projected to grow at a CAGR of 9.6% during the forecast period. Canadian healthcare practitioners engage in close collaboration with pharmaceutical corporations to increased usage of Vortioxetine.
• The Mexico Vortioxetine market is projected to witness growth at a CAGR of 9.3% during the forecast period, with a market size of USD 33.34 million in 2024.

Europe Vortioxetine

According to Cognitive Market Research, the global Vortioxetine market size was estimated at USD 915.8 Million out of which Europe held the market of more than 30% of the global revenue with a market size of USD 274.74 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031. Europe is renowned for its robust pharmaceutical research and development industry. Continual research endeavors result in the identification of novel pharmaceuticals and therapeutic alternatives. The distinctive mode of action and advantageous risk-benefit profile of vortioxetine make it appealing to both physicians and patients.

• The United Kingdom Vortioxetine market had a market share of USD 46.16 million in 2024 and is projected to grow at a CAGR of 9.9% during the forecast period. The Vortioxetine Market is boosted by the UK's strong healthcare infrastructure, research progress, and emphasis on mental health awareness.
• The France Vortioxetine market is projected to witness growth at a CAGR of 8.3% during the forecast period, with a market size of USD 25.28 million in 2024.
• According to Cognitive Market Research, the Germany Vortioxetine market size was valued at USD 54.40 million in 2024 and is projected to grow at a CAGR of 9.3% during the forecast period. The prevalence of these factors is influenced by lifestyle changes, work-related stress, and cultural influences.
• The Italy Vortioxetine market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD 23.63 million in 2024.
• The Russia Vortioxetine market is projected to witness growth at a CAGR of 8.1% during the forecast period, with a market size of USD 42.58 million in 2024.
• The Spain Vortioxetine market is projected to witness growth at a CAGR of 8.2% during the forecast period with a market size of USD 22.53 million in 2024
• The Luxembourg Vortioxetine market is projected to witness growth at a CAGR of 9.2% during the forecast period, with a market size of USD 8.52 million in 2024.
• The Portugal Vortioxetine market is projected to witness growth at a CAGR of 8.9% during the forecast period, with a market size of USD 5.77 million in 2024.
• The Greece Vortioxetine market is projected to witness growth at a CAGR of 9.4% during the forecast period, with a market size of USD 3.30 million in 2024.
• Rest of Europe's Vortioxetine market is projected to witness growth at a CAGR of 7.8% during the forecast period, with a market size of USD 42.58 million in 2024.

Asia Pacific Vortioxetine

According to Cognitive Market Research, the global Vortioxetine market size was estimated at USD 915.8 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 210.63 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.6% from 2024 to 2031. The Asia Pacific area has a substantial prevalence of depression and anxiety illnesses. Their incidence is influenced by factors such as growing urbanization, modifications to lifestyles, and social stress. The critical significance of vortioxetine in treating symptoms of depression and anxiety makes it an essential therapy choice.

• According to Cognitive Market Research, the China Vortioxetine market size was valued at USD 94.79 million in 2024 and is projected to grow at a CAGR of 12.1% during the forecast period. The market as a whole has a consistent and favorable trend, which is enticing foreign enterprises to engage in economic activities in China.
• The Japan Vortioxetine market is projected to witness growth at a CAGR of 11.1% during the forecast period, with a market size of USD 29.07 million in 2024.
• The India Vortioxetine market had a market share of USD 25.28 million in 2024 and is projected to grow at a CAGR of 14.4% during the forecast period. VORTIDIFTM strengthens Sun Pharma's dedication to the care of mental health.
• The South Korea Vortioxetine market is projected to witness growth at a CAGR of 11.7% during the forecast period, with a market size of USD 21.06 million in 2024.
• The Australia Vortioxetine market is projected to witness growth at a CAGR of 12.3% during the forecast period, with a market size of USD 10.95 million in 2024.
• The South East Asia Vortioxetine market is projected to witness growth at a CAGR of 13.6% during the forecast period, with a market size of USD 14.53 million in 2024.
• The Rest of Asia Pacific Vortioxetine market is projected to witness growth at a CAGR of 12.4% during the forecast period, with a market size of USD 14.96 million in 2024.

South America Vortioxetine

According to Cognitive Market Research, the global Vortioxetine market size was estimated at USD 915.8 Million out of which Latin America market of more than 5% of the global revenue with a market size of USD 45.79 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2024 to 2031. Latin America has a substantial weight of depression and anxiety illnesses. The incidence of these factors is influenced by urbanization, lifestyle changes, and social stress. Vortioxetine plays a significant role in treating symptoms of depression and anxiety, making it an important therapy choice.

• According to Cognitive Market Research, the Brazil Vortioxetine market size was valued at USD 19.60 million in 2024 and is projected to grow at a CAGR of 10.6% during the forecast period. The factors contributing to Brazil's increasing awareness, illness incidence, scientific achievements, and healthcare infrastructure.
• Argentina Vortioxetine market had a market share of USD 7.69 million in 2024 and is projected to grow at a CAGR of 10.9% during the forecast period. The Vortioxetine Market is seeing expansion in Argentina because to the country's increasing awareness, high illness prevalence, breakthroughs in research, and well-developed healthcare infrastructure.
• Colombia Vortioxetine market is projected to witness growth at a CAGR of 9.8% during the forecast period with a market size of USD 4.08 million in 2024.
• Peru Vortioxetine market is projected to witness growth at a CAGR of 10.2% during the forecast period with a market size of USD 3.75 million in 2024.
• Chile Vortioxetine market is projected to witness growth at a CAGR of 10.3% during the forecast period with a market size of USD 3.30 million in 2024.
• The Rest of Latin America Vortioxetine market is projected to witness growth at a CAGR of 9.1% during the forecast period, with a market size of USD 7.37 million in 2024.

Middle East and Africa Vortioxetine

According to Cognitive Market Research, the global Vortioxetine market size was estimated at USD 915.8 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 18.32 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.3% from 2024 to 2031. The Vortioxetine (ASRS) market in the Middle East and Africa is continuously expanding, owing to an increasing focus on promoting awareness of mental health. Public campaigns and educational programs emphasize the need of addressing conditions such as depression and anxiety. This heightened awareness contributes to the efficacy of vortioxetine as an antidepressant.

• The GCC Countries Vortioxetine market is projected to witness growth at a CAGR of 11.1% during the forecast period with a market size of USD 7.84 million in 2024. Their incidence is influenced by factors such as increased urbanization, lifestyle changes, and social stress.
• The Egypt Vortioxetine market is projected to witness growth at a CAGR of 10.6% during the forecast period, with a market size of USD 1.92 million in 2024.
• The South Africa Vortioxetine market is projected to witness growth at a CAGR of 11.3% during the forecast period, with a market size of USD 2.89 million in 2024. Vortioxetine sales flourish in South Africa due to Increasing spending in pharmaceutical research and development.
• The Turkey Vortioxetine market is projected to witness growth at a CAGR of 9.8% during the forecast period, with a market size of USD 1.58 million in 2024.
• The Nigeria Vortioxetine market is projected to witness growth at a CAGR of 9.4% during the forecast period, with a market size of USD 1.92 million in 2024.
• The Rest of MEA Vortioxetine market is projected to witness growth at a CAGR of 9.3% during the forecast period, with a market size of USD 2.16 million in 2024.

Vortioxetine Market Analysis

How are Segments Performing in the Global Vortioxetine Market?

Vortioxetine Market Type Segment Analysis

According to Cognitive Market Research, 10 Mg Tablet stands out as the dominating category. The 10 mg dose is often regarded as an ideal equilibrium between effectiveness and the capacity to be tolerated. Furthermore, it offers enough therapeutic efficacy in the treatment of severe depressive illness while limiting adverse reactions. Therefore, both patients and healthcare professionals may favor this dose because of its efficacy.

20 Mg Tablet emerges as the fastest-growing category in the Vortioxetine Market. Due to the rising occurrence of serious mental health illnesses, there is a need for increased doses of therapies. Psychiatric diseases, including depression, anxiety disorders, bipolar disorder, and schizophrenia, are increasingly common on a worldwide scale.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Vortioxetine Industry. Request a Free Sample PDF!

Vortioxetine Market Application Segment Analysis

According to Cognitive Market Research, the dominating category is Depression. Depression is a prevalent mental health disorder that impacts a significant number of individuals worldwide. There is a significant need for efficient antidepressants since depression is becoming more prevalent. The importance of vortioxetine in controlling depressive symptoms establishes it as an essential therapy choice.

The fastest-growing category in the Vortioxetine market is Generalized Anxiety Disorder. Generalized Anxiety Disorder (GAD) is a prevalent psychological ailment marked by an abundance of concern, unease, and enduring anxiety. The growing incidence of Generalized Anxiety Disorder (GAD) worldwide has resulted in a higher need for efficient treatment options. Vortioxetine distinguishes itself from other antidepressants due to its multimodal mode of action. As a serotonin modulator and stimulator (SMS), it has a specific action on serotonin receptors.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Vortioxetine Distribution Channel Segment Analysis

Distribution Channel Segment Analysis

According to Cognitive Market Research, the dominating category is Hospital Pharmacies. Hospitals oversee the treatment of urgent situations, which includes managing mental health emergencies. Hospital pharmacy cater to the urgent therapeutic needs of patients suffering from acute depression or anxiety. Ensuring the timely delivery of vortioxetine is made possible by its inclusion in hospital formularies.

The fastest-growing category in the Vortioxetine market is Online Pharmacies. The transition to internet platforms has revolutionized the manner in which individuals get healthcare items. Online pharmacies provide convenience by enabling people to purchase drugs from the convenience of their own homes. Vortioxetine, as an antidepressant, is advantageous in light of this trend as patients are seeking convenient and uncomplicated prescription fulfillment.

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion